Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies
Pooled result · Nephrolithiasis, pooled incidence and riskResult — go to the resultPooled relative risk 1.63 95% CI 1.33–2.00Authors' conclusion
Nephrolithiasis is a common side effect of uricosuric therapies, although the quality of evidence for this is low-moderate due to significant heterogeneity and bias.
Study context
- Population
- Adults with gout treated with uricosuric therapies; studies of asymptomatic hyperuricaemia only excluded23 studies (10 randomized controlled trials (RCTs), 13 cohort)
- Participants
- 78,042 adults
- Comparison
- Uricosuric therapies vs no uricosuric
- Uricosuricn = 15,385
- Outcome
- Incidence and risk of nephrolithiasis
Methodological detailsrandom-effects model, risk of bias assessment
- Random-effects model
- Risk of bias assessment
Pooled result
Nephrolithiasis, pooled incidence and risk
Pooled relative risk
1.63
95% CI 1.33–2.00
P = 0.001
By group
Uricosuricvs No uricosuric
pooled RR 1.63 (95% CI 1.33–2.00); P = 0.001
As reported in the abstract
Further pooled results
Pooled incidence of nephrolithiasis by study design
- 10 RCTs
- 2.87% (95% CI 1.30-4.93)
- 13 cohort studies
- 3.93% (1.95-6.44)
Original publication
Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Rheumatology (Oxford). Published 30 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →